Mobile

A Phase II trial evaluating the immunological and clinical efficay and safety of HER-2 Protein Autovac(TM) monotherapy in patients with metastatic breast cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000838-36

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the trial is to demonstrate evidence of clinical efficacy of HER-2 Protein AutoVac(TM), that is the number of evaluable patients with evidence of clinical benefit, defined as: · A complete response (CR) or partial response (PR), or · Stable disease (SD) for at least 6 months (26 weeks).

Critère d'inclusion

  • Female patients with histologically proven metastatic or locally advanced breast cancer who have HER-2 overexpression in the primary tumour and/or a metastatic lesion

Liens